Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?

International Journal of Cancer

Volumn 138, Issue 2, 2016, Pages 281-292

  Jung, Ji Won ^a   Overgaard, Nana H ^a,b   Burke, Michael T ^a   Isbel, Nicole ^a   Frazer, Ian H ^a   Simpson, Fiona ^a   Wells, James W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Mental Health Center Glostrup   (Denmark)

Author keywords

immunosuppression; nonmelanoma skin cancer; organ transplant recipient; T cells

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ADVERSE EFFECTS; ANIMAL; DRUG EFFECTS; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ORGAN TRANSPLANTATION; RISK FACTOR; SKIN TUMOR; T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RISK FACTORS; SKIN NEOPLASMS; T-LYMPHOCYTES; TRANSPLANT RECIPIENTS;

EID: 84955632950     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29450     Document Type: Review

References (121)

1. Kasiske BL, Snyder JJ, Gilbertson DT, et al., Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-13.
2. Vajdic CM, McDonald SP, McCredie MR, et al., Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-31.
3. Haagsma EB, Hagens VE, Schaapveld M, et al., Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91.
4. Aberg F, Pukkala E, Hockerstedt K, et al., Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl 2008; 14: 1428-36.
5. Silverberg MJ, Leyden W, Warton EM, et al., HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013; 105: 350-60.
6. Jensen AO, Olesen AB, Dethlefsen C, et al., Chronic diseases requiring hospitalization and risk of non-melanoma skin cancers-a population based study from Denmark. J Invest Dermatol 2008; 128: 926-31.
7. Agnew KL, Ruchlemer R, Catovsky D, et al., Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004; 150: 1129-35.
8. Grulich AE, van Leeuwen MT, Falster MO, et al., Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
9. Lindelof B, Sigurgeirsson B, Gabel H, et al., Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143: 513-9.
10. Ramsay HM, Fryer AA, Hawley CM, et al., Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147: 950-6.
11. Vajdic CM, van Leeuwen MT., Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747-54.
12. Abou Ayache R, Thierry A, Bridoux F, et al., Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy. Transplant Proc 2007; 39: 2592-4.
13. Mackintosh LJ, Geddes CC, Herd RM., Skin tumours in the West of Scotland renal transplant population. Br J Dermatol 2013; 168: 1047-53.
14. McDonald S, Clayton P, Hurst K., Australia and New Zealand Dialysis and Transplant Registry; 2012. Annual report-35th Edition.
15. Dantal J, Hourmant M, Cantarovich D, et al., Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-8.
16. Otley CC, Berg D, Ulrich C, et al., Reduction of immunosuppression task force of the international transplant skin cancer c, the skin care in organ transplant patients E. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006; 154: 395-400.
17. Mathew T, Kreis H, Friend P., Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-9.
18. Ingvar A, Smedby KE, Lindelof B, et al., Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant 2010; 25: 2764-71.
19. Rabinovics N, Mizrachi A, Hadar T, et al., Cancer of the head and neck region in solid organ transplant recipients. Head Neck 2014; 36: 181-6.
20. Eisen HJ, Kobashigawa J, Keogh A, et al., Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517-25.
21. Robson R, Cecka JM, Opelz G, et al., Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-60.
22. Allison AC, Hovi T, Watts RW, et al., The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977: 207-24.
23. Kelley WN, Rosenbloom FM, Seegmiller JE., The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism. J Clin Invest 1967; 46: 1518-29.
24. Patel AA, Swerlick RA, McCall CO., Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-89.
25. Swann PF, Waters TR, Moulton DC, et al., Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-11.
26. Tiede I, Fritz G, Strand S, et al., CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45.
27. Thomas CW, Myhre GM, Tschumper R, et al., Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Therap 2005; 312: 537-45.
28. Sintchak MD, Fleming MA, Futer O, et al., Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921-30.
29. Carr SF, Papp E, Wu JC, et al., Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286-90.
30. Allison AC., Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 Suppl 1: s2-8.
31. Marsland AM, Griffiths CE., The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12: 618-22.
32. Al-Daraji WI, Grant KR, Ryan K, et al., Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002; 118: 779-88.
33. Shaw RJ, Cantley LC., Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30.
34. Jacinto E, Loewith R, Schmidt A, et al., Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-8.
35. Brown EJ, Albers MW, Shin TB, et al., A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
36. Delgoffe GM, Kole TP, Zheng Y, et al., The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30: 832-44.
37. Araki K, Turner AP, Shaffer VO, et al., mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-12.
38. Rao RR, Li Q, Odunsi K, et al., The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010; 32: 67-78.
39. Euvrard S, Morelon E, Rostaing L, et al., Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-39.
40. Campbell SB, Walker R, Tai SS, et al., Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146-56.
41. Salgo R, Gossmann J, Schofer H, et al., Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10: 1385-93.
42. Alberu J, Pascoe MD, Campistol JM, et al., Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303-10.
43. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al., Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013; 31: 1317-23.
44. Zwald FO, Brown M., Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253-61; quiz 62.
45. Yaich S, Charfeddine K, Zaghdane S, et al., Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases. Transplant Proc 2012; 44: 2824-6.
46. Gutierrez-Dalmau A, Sanchez-Fructuoso A, Sanz-Guajardo A, et al., Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 2005; 37: 3836-8.
47. Stallone G, Schena A, Infante B, et al., Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-23.
48. Roy D, Sin SH, Lucas A, et al., mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res 2013; 73: 2235-46.
49. Nichols LA, Adang LA, Kedes DH., Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PloS One 2011; 6: e14535.
50. Kaymakcalan MD, Je Y, Sonpavde G, et al., Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer 2013; 108: 2478-84.
51. Feldmeyer L, Hofbauer GF, Boni T, et al., Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. Br J Dermatol 2012; 166: 422-4.
52. O'Donovan P, Perrett CM, Zhang X, et al., Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-4.
53. Gueranger Q, Li F, Peacock M, et al., Protein oxidation and DNA repair inhibition by 6-thioguanine and UVA radiation. J Invest Dermatol 2014; 134: 1408-17.
54. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al., Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-28 e1-5.
55. van den Reek JM, van Lumig PP, Janssen M, et al., Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol 2014; 28: 27-33.
56. O'Neill JO, Edwards LB, Taylor DO,. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 1186-91.
57. Koehl GE, Wagner F, Stoeltzing O, et al., Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 2007; 83: 607-14.
58. Liu W, Xu J, Wang M, et al., Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol 2011; 39: 1213-20.
59. Guba M, von Breitenbuch P, Steinbauer M, et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
60. Wu X, Nguyen BC, Dziunycz P, et al., Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010; 465: 368-72.
61. Dziunycz PJ, Lefort K, Wu X, et al., The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. J Invest Dermatol 2014; 134: 1998-2004.
62. Lin HL, Lui WY, Liu TY, et al., Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer 2003; 88: 973-80.
63. Maluccio M, Sharma V, Lagman M, et al., Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597-602.
64. Hojo M, Morimoto T, Maluccio M, et al., Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-4.
65. Thoms KM, Kuschal C, Oetjen E, et al., Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression. Exp Dermatol 2011; 20: 232-6.
66. Luan FL, Hojo M, Maluccio M, et al., Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565-72.
67. Birchmeier W, Weidner KM, Hulsken J, et al., Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas. Semin Cancer Biol 1993; 4: 231-9.
68. Brouxhon SM, Kyrkanides S, Raja V, et al., Ectodomain-specific E-cadherin antibody suppresses skin SCC growth and reduces tumor grade: a multi-targeted therapy modulating RTKs and the PTEN-p53-MDM2 axis. Mol Cancer Therap 2014; 13: 1791-802.
69. Karayannopoulou G, Euvrard S, Kanitakis J., Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients. Anticancer Res 2013; 33: 3711-4.
70. Chaudhary SC, Kurundkar D, Elmets CA, et al., Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol 2012; 88: 1149-56.
71. Kurundkar D, Srivastava RK, Chaudhary SC, et al., Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol 2013; 266: 233-44.
72. Herzog A, Bian Y, Vander Broek R, et al., PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 2013; 19: 3808-19.
73. Saha B, Cypro A, Martin GM, et al., Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN-deficient human fibroblasts. Aging Cell 2014; 13: 573-5.
74. Liu M, Howes A, Lesperance J, Stallcup WB, et al., Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 2005; 65: 5325-36.
75. Sully K, Akinduro O, Philpott MP, et al., The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBalpha isoform signaling. Oncogene 2013; 32: 3254-62.
76. Aissat N, Le Tourneau C, Ghoul A, et al., Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62: 305-13.
77. Russell JJ., Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Physician 2002; 66: 1899-902.
78. Thaci D, Salgo R., Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52-6.
79. Naylor M, Elmets C, Jaracz E, et al., Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatol Treat 2005; 16: 149-53.
80. Babel N, Eibl N, Ulrich C, et al., Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transplant Infect Dis 2008; 10: 59-62.
81. Boratynska M, Zmonarski SC, Klinger M., Reccurence of Kaposi's sarcoma after increased exposure to sirolimus. Int Immunopharmacol 2006; 6: 2018-22.
82. Ben-Horin S, Goldstein I, Fudim E, et al., Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut 2009; 58: 396-403.
83. Leitner J, Drobits K, Pickl WF, et al., The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals. Immunol Lett 2011; 140: 74-80.
84. Quemeneur L, Flacher M, Gerland LM, et al., Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002; 169: 2747-55.
85. Allison AC, Eugui EM., Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80: S181-90.
86. He X, Smeets RL, Koenen HJ, et al., Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation. Am J Transplant 2011; 11: 439-49.
87. Salinas-Carmona MC, Perez LI, Galan K, et al., Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB/c mice. Autoimmunity 2009; 42: 537-44.
88. Bhandaru M, Pasham V, Yang W, et al., Effect of azathioprine on Na(+)/H(+) exchanger activity in dendritic cells. Cell Physiol Biochem 2012; 29: 533-42.
89. Pols TW, Bonta PI, Pires NM, et al., 6-Mercaptopurine inhibits atherosclerosis in apolipoprotein e∗3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler Thromb Vasc Biol 2010; 30: 1591-7.
90. Karnell JL, Karnell FG, III, Stephens GL, et al., Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol 2011; 187: 3603-12.
91. Faugaret D, Lemoine R, Baron C, et al., Mycophenolic acid differentially affects dendritic cell maturation induced by tumor necrosis factor-alpha and lipopolysaccharide through a different modulation of MAPK signaling. Mol Immunol 2010; 47: 1848-59.
92. Brehm C, Huenecke S, Esser R, et al., Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. Cancer Immunol Immunother 2014; 63: 821-33.
93. Lee YR, Yang IH, Lee YH, et al., Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005; 105: 3951-5.
94. Hackstein H, Taner T, Zahorchak AF, et al., Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-63.
95. Heidt S, Roelen DL, Eijsink C, et al., Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol 2010; 159: 199-207.
96. Naranjo-Gomez M, Climent N, Cos J, et al., Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion. Immunology 2006; 119: 488-98.
97. Tiefenthaler M, Hofer S, Ebner S, et al., In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression. Nephrol Dial Transplant 2004; 19: 553-60.
98. Miroux C, Morales O, Ghazal K, et al., In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation 2012; 94: 123-31.
99. Gao W, Lu Y, El Essawy B, et al., Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7: 1722-32.
100. Maloy KJ, Powrie F., Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2: 816-22.
101. Carroll RP, Segundo DS, Hollowood K, et al., Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010; 21: 713-22.
102. Zhang S, Fujita H, Mitsui H, et al., Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PloS One 2013; 8: e62154.
103. Hope CM, Grace BS, Pilkington KR, et al., The immune phenotype may relate to cancer development in kidney transplant recipients. Kidney Int 2014; 86: 175-83.
104. Muhleisen B, Petrov I, Gachter T, et al., Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. Histopathology 2009; 55: 67-76.
105. Carroll RP, Hester J, Wood KJ, et al., Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant 2013; 28: 462-5.
106. Sinclair LV, Finlay D, Feijoo C, et al., Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 2008; 9: 513-21.
107. Haidinger M, Poglitsch M, Geyeregger R, et al., A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010; 185: 3919-31.
108. Cao W, Manicassamy S, Tang H, et al., Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008; 9: 1157-64.
109. Zhang S, Pruitt M, Tran D, et al., B cell-specific deficiencies in mTOR limit humoral immune responses. J Immunol 2013; 191: 1692-703.
110. Jagannath C, Lindsey DR, Dhandayuthapani S, et al., Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 2009; 15: 267-76.
111. Baker AK, Wang R, Mackman N, et al., Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. Mol Immunol 2009; 46: 2249-55.
112. Amiel E, Everts B, Freitas TC, et al., Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol 2012; 189: 2151-8.
113. Brouard S, Puig-Pey I, Lozano JJ, et al., Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. Am J Transplant 2010; 10: 2604-14.
114. Anderson BE, Tang AL, Wang Y, et al., Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4(+) effector memory T cells. Eur J Immunol 2011; 41: 2782-92.
115. Powell DJ, Jr., Dudley ME, Robbins PF, et al., Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005; 105: 241-50.
116. Jones DL, Sacks SH, Wong W., Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants. Transplantation 2006; 82: 1352-61.
117. Tsuda K, Yamanaka K, Kitagawa H, et al., Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. PloS One 2012; 7: e31465.
118. Powell JD, Delgoffe GM., The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010; 33: 301-11.
119. Kaech SM, Cui W., Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012; 12: 749-61.
120. Lucas CL, Kuehn HS, Zhao F, et al., Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol 2014; 15: 88-97.
121. Rovira J, Sabet-Baktach M, Eggenhofer E, et al., A color-coded reporter model to study the effect of immunosuppressants on CD8+ T-cell memory in antitumor and alloimmune responses. Transplantation 2013; 95: 54-62.